United Therapeutics (Nasdaq:UTHR) has settled its patent suit with Actavis Labortories, FL, a subsidiary of Teva Pharmaceuticals, over patents related to its hyptension drug Orenitram.

The drug brought in more than $157 million to United Therapeutics in 2016.

The settlement lets Actavis make and commercialize a generic version of Orenitram starting June 2027, or earlier under certain cases.

The agreement specifically does not allow Actavis to sell generic versions of its other products, including Tyvaso and Remodulin.